Medical Technology Investor Alert: Medical Alarm Concepts Holding, Inc. (MDHI) Receives Strategic Investment to Continue Strong Growth - Moves into Positive Operating Cash Flow for March 2013 Quarter

KING OF PRUSSIA, Pa. - March 6, 2013 (Investorideas.com Newswire) Medical Alarm Concepts Holding, Inc. (OTCQB:MDHI), today announced it has received an investment led by strategic partner, JTT-EMS LTD of Shijiazhuang, China. Under the terms of the investment, JTT-EMS purchased restricted common stock, which it plans to hold as a long-term investment. The financing, including additional investments by current shareholders, will total approximately $330,000.
"This is exciting financing for our Company that will allow us to maintain our strong growth," commented Ronnie Adams, CEO. "This strategic investment is straight common equity in the Company, which must be held for an extended period of time. There are no warrants, options, or any other enhancements. Over the past two quarters our business has turned the corner with strong growth, allowing us to reach positive cash flow. Because this growth is based on high quality recurring monthly revenues, we believe the positive operating cash flow we will report beginning in the March 2013 quarter will be sustainable moving forward."
The demand for the MediPendant® continues to grow at a rapid pace as a result of strong sales from the Company's retail partnership and growing online orders. Medical Alarm Concepts recently announced the signing of a major diversified national healthcare insurer that will offer the Company's MediPendant® product and monthly monitoring services to subscribers of selected healthcare programs. Additionally, the product will be included in the insurance carrier's dual demonstration program (Medicaid and Medicare) related contracts on which it may bid.


Use of funds from this new strategic investment will be primarily for inventory acquisition to meet growing demand. Secondary uses of funds will include completing the process of restoring the Company to fully reporting status, additional marketing programs, further reductions in trade payables, and general working capital.
The MediPendant® is a second-generation personal medical alarm and the only product in its category that allows for monitored, two-way communications and associated voice prompts directly through the pendant. Older generations of technology require the user to be in close proximity to the base station in order to speak and listen to the operator. With the MediPendant®, the customer can be anywhere within 600+ feet of their home, and in the event of an emergency, speak and listen to the EMT trained operator directly through the pendant.
Additional information on the MediPendant® can be viewed at www.MediPendant.com.
About MDHI
Medical Alarm Concepts Holdings, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant's® patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant® service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time. Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. A standard PERS system does not enable the user to speak and listen through the pendant, thus limiting them to a small area in their home. There is always the risk that the user will not be heard by the call center operator if they are not within a short range of the base station.
Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.
Contact:
Medical Alarm Concepts Holding, Inc.
877-639-2929 Ext. 113
Paid News published at Investorideas.com Newswire:
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure :MDHI: March 2013 news and content distribution Investorideas.com newswire and syndication partners : $five thousand
More: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Alert; 8K Filing; Medical Alarm Concepts Holding, Inc. (OTC: MDHI) to become a provider of personal medical alarms for Coventry Health Care, Inc. (NYSE: CVH)

Point Roberts, WA - March 5, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for investors, issues an 8K filing alert for medical device company, Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK).

According to the filing: "On February 25, 2013, the Company signed a supply and services contract with Coventry Health Care, Inc., (NYSE: CVH) a diversified national insurer in the United States located in Bethesda, Maryland, which operates health plans, insurance companies, network rental and workers' compensation services companies.
Medical Alarm Concepts Holding, Inc. will become a provider of personal medical alarms for Coventry.
Under the terms of the agreement, Coventry Health Care, Inc. will offer the Company's MediPendant® product and monthly monitoring services to subscribers of selected healthcare programs provided by Coventry. Additionally, the Company's MediPendant® product has been, or may be, included in their dual demonstration programs (Medicare and Medicaid) related contracts on which Coventry Health Care, Inc. may bid.
The Company is expecting this contract to generate growth in revenue and earnings. As a result of gaining the contract, the Company plans to expand its business operations in the areas of manufacturing, financial management, research & development, and logistics."
http://www.sec.gov/Archives/edgar/data/1443089/000147124213000073/mdhifeb262013.htm
Full news: http://www.investorideas.com/news/2013/biotech/03041.asp
Additional information on the MediPendant can be viewed at www.MediPendant.com .
About MDHI (OTCQB: MDHI.PK),
Medical Alarm Concepts Holdings, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant's™ patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant™ service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time.  Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. A standard PERS system does not enable the user to speak and listen through the pendant, thus limiting them to a small area in their home. There is always the risk that the user will not be heard by the call center operator if they are not within a short range of the base station.
Medical Alarm Concepts Holding, Inc.
Contact:
Medical Alarm Concepts Holding, Inc.
877-639-2929 Ext. 113
Paid News published at Investorideas.com Newswire:
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure :MDHI: March 2013 news and content distribution Investorideas.com newswire and syndication partners : $five thousand
More: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com 800 665 0411

Medical Alarm Concepts (MDHI) Trades Up on News Gaining over 23%

Point Roberts, WA - March 4, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for investors, issues a trading alert for medical device company, Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK). The stock is trading up over 23% on over 9 Million shares following news.


The Company released an update today with details about its recently accelerating growth rate and a contract signed with a diversified national insurer where Medical Alarm Concepts will become a provider of personal medical alarms.
According to the release, "Under the terms of the new agreement, the diversified national insurer will offer the Company's MediPendant® product and monthly monitoring services to subscribers of selected healthcare programs. Additionally, the Company's MediPendant® product has been, or may be, included in their dual demonstration programs (Medicare and Medicaid) related contracts on which Coventry Health Care, Inc.( NYSE:CVH ) may bid. Additional information regarding this contract can be viewed on the website hosted by the US Securities & Exchange Commission at the following link:” http://www.sec.gov/Archives/edgar/data/1443089/000147124213000073/mdhifeb262013.htm
Full news: http://www.investorideas.com/news/2013/biotech/03041.asp
Additional information on the MediPendant can be viewed at www.MediPendant.com .
About MDHI ( OTCQB: MDHI.PK ),
Medical Alarm Concepts Holdings, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant's™ patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant™ service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time.  Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. A standard PERS system does not enable the user to speak and listen through the pendant, thus limiting them to a small area in their home. There is always the risk that the user will not be heard by the call center operator if they are not within a short range of the base station.
Medical Alarm Concepts Holding, Inc.
Contact:
Medical Alarm Concepts Holding, Inc.
877-639-2929 Ext. 113
Paid News published at Investorideas.com Newswire:
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure :MDHI: March 2013 news and content distribution Investorideas.com newswire and syndication partners : $five thousand
More: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com 800 665 0411

Medical Technology Investor Alert: Medical Alarm Concepts (MDHI) Signs Deal with Health Care Insurance Provider for Medical Alarms

KING OF PRUSSIA, PA - March 4, 2013 (Investorideas.com Newswire) Medical Alarm Concepts Holding, Inc. ( OTCQB: MDHI.PK ), today provided details about its recently accelerating growth rate and a contract signed with a diversified national insurer where Medical Alarm Concepts will become a provider of personal medical alarms.

Under the terms of the new agreement, the diversified national insurer will offer the Company's MediPendant® product and monthly monitoring services to subscribers of selected healthcare programs. Additionally, the Company's MediPendant® product has been, or may be, included in their dual demonstration programs (Medicare and Medicaid) related contracts on which Coventry Health Care, Inc.( NYSE:CVH ) may bid. Additional information regarding this contract can be viewed on the website hosted by the US Securities & Exchange Commission at the following link:
http://www.sec.gov/Archives/edgar/data/1443089/000147124213000073/mdhifeb262013.htm
Mr. Ronnie Adams commented, "We are expecting this contract to generate growth in revenues and earnings. As a result of gaining this contract, we plan to expand our business operations in the areas of manufacturing, financial management, research and development, and logistics.”
Over the past few months Medical Alarm Concepts has been experiencing strong growth in revenues due to an expanding retail presence, strong Internet sales and new international opportunities. Having now reached operational cash flow profitability, the Company is expecting to report positive cash flow for the full quarter ending March 31, 2013 and throughout calendar 2013.
"We are very pleased that our cash flow will be based on very high quality recurring revenues. Our retail partnerships remain strong. This week we began the first of two promotions that are scheduled for the late winter and early spring period. Thus far, sales have been extremely robust, which is strongly adding to our recurring monthly revenue base. We are expecting calendar 2013 to be a year of very strong growth and cash flow.
The MediPendant is a second-generation personal medical alarm and the only product in its category that allows for monitored, two-way communications directly through the pendant along with patented voice prompts. Older generations of technology require the user to be in close proximity to the base station in order to speak and listen to the operator. With the MediPendant the customer can be anywhere within approximately 600 feet of their home and in the event of an emergency speak and listen to the EMT trained operator directly through the pendant.
Additional information on the MediPendant can be viewed at www.MediPendant.com .
About MDHI ( OTCQB: MDHI.PK ),
Medical Alarm Concepts Holdings, Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant's™ patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant™ service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time.  Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. A standard PERS system does not enable the user to speak and listen through the pendant, thus limiting them to a small area in their home. There is always the risk that the user will not be heard by the call center operator if they are not within a short range of the base station.
Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.
SOURCE: Medical Alarm Concepts Holding, Inc.
Contact:
Medical Alarm Concepts Holding, Inc.
877-639-2929 Ext. 113
Paid News published at Investorideas.com Newswire:
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure :MDHI: March 2013 news and content distribution Investorideas.com newswire and syndication partners : $five thousand
More: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer

SAN DIEGO - February 28, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

I recently attended a healthcare related event that featured a panel discussion comprised of life science bankers and venture capitalists. While members of this panel often had differing viewpoints, they did mutually agree they were interested in emerging therapeutic candidates that provided more than one "shot on goal," meaning the possibility of a single therapy that could address more than one disease indication.
In the case of the Aethlon Hemopurifier®, we have created a therapeutic filtration device that selectively captures a broad-spectrum of disease promoting particles from circulation without eliminating blood components required for health. However, instead of immobilizing an antibody or agent that specifically binds to a single pathogen, we made the bold decision to deploy the capabilities of a lectin affinity agent that binds to a unique structure evolved and shared by viruses and cancer as a survival mechanism that allows disease progression to continue below the surveillance of the immune system. In the treatment of Hepatitis C virus (HCV), we have demonstrated that our Hemopurifier® can eliminate the presence of HCV in as little a seven days when utilized in combination with interferon-based therapy. Short-term administration of the same device has reduced viral load by greater than 90% in an HIV-AIDS dialysis patient who was not receiving any form of antiviral drug therapy. Additionally, government and non-government research organizations have demonstrated the Hemopurifier® captures a wide range of bioterror and pandemic threats. In regards to cancer, the same Hemopurifier® deployed in infectious disease studies has emerged to be the first therapeutic strategy to address tumor-secreted exosomes. Tumor-secreted exosomes are a vital therapeutic target as they have recently been discovered to be immunosuppressive and play significant role in seeding the creation and spread of cancer metastasis.
So, how is it possible that one therapy can address a breadth of disease conditions? Dr. Annette Marleau, our Director of Tumor Immunology provides the following summary review for interested parties, including medical and non-medical industry shareholders of Aethlon Medical:
Intriguingly, there are converging biological mechanisms underlying viral infections and cancer, despite the fact that these are distinct categories of disease that are typically addressed with different therapies. Common disease processes in infections and cancer include the modalities by which disease is spread and the involvement of the immune system. The latter point stems from the fact that both tumor cells and infectious pathogens are viewed as "foreign invaders" by the immune system. In response, diseased cells have evolved tactics for manipulating the immune system to their advantage in order to propagate disease. One of the key pathogenic maneuvers employed by viruses and tumors is the systemic distribution of disease-mediating particles that spread molecular information from diseased cells to healthy cells.
Of relevance to our Hemopurifier® is the observation that critical disease-mediating particles in many viral infections and cancer display high-mannose glycoproteins on their surfaces. These surface features arise during the process of glycosylation, whereby carbohydrate residues such as mannose are tagged onto proteins to ensure proper protein assembly and function in healthy cells. Not surprisingly, this process becomes perturbed in several disease conditions, thereby changing the biologic functions of proteins. To define the glycoprotein signatures associated with specific disease conditions, researchers have applied panels of carbohydrate-binding proteins (lectins) to determine the relative compositions of specific carbohydrate residues in cellular material. Extrapolating on the use lectins as research reagents for biomarker discovery, our device platform leverages the specificity of lectins for glycoprotein-coated particles for therapeutic affinity capture.
Among the spectrum of targets of the Hemopurifier® are enveloped viruses, a broad group of infectious pathogens that are enriched for high-mannose glycoproteins on their outer surfaces. The envelope glycoproteins have well-recognized roles in viral attachment and integration into host cells (1). Scientific studies have demonstrated that lectins have potent anti-viral activity by virtue of their interference with the functions of envelope glycoproteins. Indeed, the current version of the Hemopurifier® has been demonstrated to capture a spectrum of enveloped viruses including HIV, Dengue virus, orthopoxviruses (vaccinia and monkeypox), influenza viruses (H5N1 bird flu, 1918 Spanish flu), and Ebola.
In addition to addressing viral infections, the Hemopurifier also captures cancer-derived exosomes that also display high-mannose glycoproteins on their outer surfaces (2). Exosomes are membranous nanovesicles secreted by diverse tumor types that act as inter-cellular messengers to spread oncogenic signals. Evidence is emerging that cancer exosomes are involved in practically every aspect of malignancy, including apoptosis of immune cells, tissue invasion, angiogenesis, metastases and resistance to therapeutic drugs. The genomic and proteomic content of exosomes, as well as the exosome load in the circulation, are known to correlate with tumor stage and metastasis, suggesting that exosomes can serve as disease biomarkers (3,4). Accordingly, exosomes have emerged as critical targets in cancer care, and there is currently an unmet need for means of targeting these nanovesicles therapeutically.
Based on their common glycoprotein signatures, the biogenesis of virions and exosomes has been suggested to share a conserved evolutionary pathway (5). These nano-sized particles (both in the 50-300 nm range) use their heavily glycosylated surfaces for entry into target cells, where virions and exosomes transfer pathogenic information in the form of proteins and/or genetic material. These particles also hijack the intracellular machinery to affect cell growth and survival pathways, while also promoting the formation of more disease-mediating particles. Indeed, newly generated virions and exosomes are both secreted by budding off from the plasma membrane of diseased cells, during which time it is believed they inherit glycoprotein-rich membrane components (6). Thus, the fields of viral and cancer immunology converge mechanistically at the level of the glycoprotein "fingerprints" on key disease-mediating particles.
The intersection of the pathways exploited by virions and exosomes is exemplified by the ability of certain viruses to package their infectious material into exosomes. For example, HIV-infected cells secrete exosomes containing Nef or "Negative Factor", an abundant HIV protein that induces death of CD4+ T cells, a hallmark of AIDS (7). Viruses and exosomes can therefore act as co-dependent entities for spreading infection and impeding host immunity. A validation study conducted by our collaborators at the Morehouse School of Medicine revealed that the Hemopurifier® captures NEF exosomes and therefore holds promise as an anti-viral strategy for co-targeting both Nef exosomes and HIV virions in circulation.
Collectively, these lines of evidence provide a compelling scientific rationale for why the Hemopurifier® is a candidate broad-spectrum countermeasure against both viral pathogens and cancer. In both of these clinical scenarios, we propose to advance the Hemopurifier as an adjunct to standard of care therapies for reducing the systemic burden of disease-mediating particles and unmasking the native immune response in patients.
(1) Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 2007;5:583.
(2) Batista BS et al. Identification of a conserved glycan signature for microvesicles. J Proteome Res 2011;10:4624.
(3) Taylor DD and Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 2011;33:441.
(4) Henderson MC and Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2012;2:38.
(5) Krishnamoorthy L et al. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol 2009;5:244.
(6) Wurdinger T et al. Extracellular vesicles and their convergence with viral pathways. Adv Virol 2012:767694.
(7) Lenassi M et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010;11:110.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biodefense Stock Alert: PositiveID (OTCBB:PSID) Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3

DELRAY BEACH, Fla. - February 7, 2013 (Investorideas.com Newswire) PositiveID Corporation (OTCBB: PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.

William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe that PositiveID is well positioned for BioWatch Generation 3, as our M-BAND detection technology (Microfluidics-based BioAgent Autonomous Networked Detector) was the only system of its kind successfully demonstrated in the field as part of the DHS Science & Technology Directorate ("S&T") BAND (BioAgent Autonomous Networked Detector) Program. In October 2012, we issued a corporate update to our stockholders about the BioWatch program, stating that we were in discussions with strategic partners to manufacture and sell M-BAND, and reiterating our belief that the BioWatch program would soon begin to roll out. The release of the draft RFP for Stage 1 of BioWatch Generation 3 validates this belief and re-confirms the U.S. Government's focus on protecting the nation from biological threats. Moreover, in the fourth quarter of 2012, we announced that we entered into two agreements with large strategic partners that we believe position us effectively to deliver critical detection systems for our homeland defense."
For more information on these announcements, please click on the following links:
http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=728046
http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=718902
About M-BAND and Dragonfly
PositiveID's M-BAND technology, developed under contract with DHS S&T, is a bio-aerosol monitor with fully integrated systems for sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins. Results are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments. PositiveID's Dragonfly system is designed to deliver molecular diagnostic results from a sample in less than 30 minutes, which would enable accurate diagnostics leading to potential treatment scenarios at the point of care that are not possible with existing systems. Dragonfly is being developed further for a broad range of biological detection situations including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus ("MRSA") and human papilloma virus ("HPV").
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection and diagnostics systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including, without limitation, the likelihood that the final RFP for Stage 1 of BioWatch Generation 3 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th; the likelihood that the Stage 1 contract is expected to have a performance period of 18 months; the likelihood that the full roll-out of BioWatch Generation 3 is estimated at $3.1 billion; the likelihood that PositiveID is well positioned for BioWatch Generation 3 as its M-BAND detection technology was the only system of its kind successfully demonstrated in the field as part of the DHS S&T BAND Program; the likelihood that the Company's two agreements with large strategic partners position the Company effectively to deliver critical detection systems for our homeland defense; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, PositiveID's ability to successfully pursue the BioWatch Generation 3 opportunity; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, as amended on May 4, 2012, and 10-Qs filed on November 16, 2012, August 20, 2012, as amended on September 12, 2012, and May 14, 2012, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Published at Investorideas.com News wire
More info on PSID
http://www.investorideas.com/CO/PSID/
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure PSID is a featured company on Investorideas.com and has compensated the company in the past . Investorideas.com is currently long PSID shares. www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: Since September 30th, 2011 / Thank You Shareholders

SAN DIEGO - February 5, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

In our quest to innovate life-saving therapeutics, we have persevered through untold challenges to create a single medical device that offers to optimize the benefit of cancer and infectious disease therapies. As our endeavors transitioned beyond R&D, we thought we were cognizant of the entire alphabet soup of healthcare and financial regulatory agencies we would need to navigate to bring our technology to market.
However, on September 30th 2011, we were blindsided by an action never anticipated. The Depository Trust Company (DTC) eliminated the electronic transfer of our securities, otherwise known as a "DTC Chill." As a result, broker-dealers across America began to restrict or prohibit trading in Aethlon Medical shares, which in turn reduced liquidity and inhibited the true sentiment for our company to be accurately reflected by the public markets. A recently published viewpoint of a securities law firm provides a more succinct perspective on a DTC Chill:
"The Depository Trust Company is the only stock depository in the U.S. When DTC provides services as the depository for an issuer's securities, its securities can trade electronically. Without DTC eligibility, it is almost impossible for an issuer to establish an active market in its securities."
As the result of protracted legal effort, DTC has agreed to lift the restriction on the electronic transfer of our securities, which we reported in an SEC filing on January 7th. In a related event, I am pleased to inform shareholders and other interested parties that our transfer agent has notified us that the CUSIP underlying our shares is now unlocked to again allow for our shares to be electronically traded on the DTC system. Thus, signaling the end of a lengthy and disheartening challenge faced by our organization.
While we cannot measure the full impact the DTC Chill, I ask you to consider some of our milestone achievements since September 30th, 2011. Milestone achievements that many biotechnology or medical device organizations would envy.
On the day (yes, the exact same day) the DTC Chill went into effect, we transitioned from a development-stage to revenue-stage organization as the result of a $6.8 Department of Defense (DOD) contract award from the Defense Advanced Research Projects Agency (DARPA). Since contract initiation, we have generated in excess of $2 million in revenues and have advanced the development of a device and blood processing system to combat sepsis.
Related to our DARPA program, we teamed with two larger industry organizations to respond to a $25 million systems integrator contract opportunity. The recipient of this contract has not yet been announced by DARPA.
We reported our first Hepatitis-C (HCV) efficacy data related to the use of our Hemopurifier® as an adjunct to optimize the benefit of standard of care drug therapy. The results exceeded expectations as a three-treatment Hemopurifier® protocol was demonstrated to reduce viral load to undetectable levels in as little as seven days. Since September 30th, 2011, organizations with clinical stage adjunct therapies have been acquired for a much as $11 Billion.
Based on prior discussions with the U.S. Food and Drug Administration (FDA), we established a protocol to elute the post-treatment biological fluid from the Hemopurifier® as a means to quantify HCV capture. The result established an unprecedented data point validating the capture of up to 300 billion copies of HCV during a single treatment. I plan to detail the relevance of this datapoint in a future CEO note.
As the result of our HCV treatment outcomes, the Medanta Medicity Institute is now offering Hemopurifier® therapy on a compassionate-use basis to HCV-infected individuals.
We submitted an Investigational Device Exemption (IDE) to the FDA to request permission to initiate a clinical feasibility study HCV infected individuals who would be enrolled to receive Hemopurifier® therapy. We have since received comments and study design considerations back from FDA and are preparing a response that we hope will lead to the initiation of U.S. clinical studies.
Since September 30th, 2011, we advanced studies that validated the ability of our Hemopurifier® to capture exosomes underlying different forms of cancer. Tumor-secreted exosomes have been discovered to play a vital role in cancer progression and it has recently become clear that a successful war against cancer will need to address these particles. Our Hemopurifier® is the first therapeutic candidate to address tumor-secreted exosomes.
We expanded our intellectual property portfolio of pending and issued patents. As the result of our early exosome research, we were recently issued a patent that protects our cancer treatment strategy in the United States for the next two decades.
We disclosed that researchers at the Morehouse School of Medicine discovered that the Hemopurifier® captures HIV exosomes, which transport NEF protein to assist HIV in maintaining the suppression of the immune system, even when antiviral drugs are able to achieve undetectable viral load in treated patients.
We began shipping our exosome assay (ELLSA), which we originally created to support our own research, to researchers who are utilizing its capabilities to create new diagnostic tools that have the potential to identify a variety of disease conditions in blood and urine.
We received the support of highly regarded thought leaders from the extracorporeal, sepsis, and cancer field who agreed to join our science advisory board.
We believe that these selected achievements portray a company that is making significant progress despite the challenges of being a small public company that was saddled with a DTC Chill since September 30th, 2011.
In closing, I am forever grateful to those shareholders that have loyally supported our endeavors even in the darkest moments. Your belief validates many sacrifices and inspires the strength to continue waging every fight necessary to ensure our innovation has the opportunity to save lives.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894